

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	26.6	67.6	(40.1-106.9)	Male	11	14.9	73.7	(36.7-131.8)
Female	10	9.5	105.0	(50.3-193.2)	Female	15	11.6	129.2	(72.3-213.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.1	155.9	(67.1-307.3)	Male	1	4.0	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	Female	9	3.0	300.5	(137.1-570.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	13	13.7	94.8	(50.4-162.2)
Female	96	95.0	101.1	(81.9-123.5)	Female	9	12.1	74.6	(34.0-141.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.2	nc	(nc-nc)	Male	8	10.0	80.2	(34.5-158.0)
<u>Colon / Rectum</u>					Female	6	4.6	129.6	(47.3-282.2)
Male	44	39.8	110.6	(80.3-148.4)	<u>Ovary</u>				
Female	38	37.7	100.8	(71.3-138.4)	Female	9	10.2	88.0	(40.2-167.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.8	133.1	(60.7-252.7)	Male	7	7.5	93.2	(37.3-192.0)
Female	0	1.9	nc	(nc-nc)	Female	4	8.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.1	nc	(nc-nc)	Male	90	102.6	87.7	(70.5-107.8)
Female	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	6.8	220.4	(123.3-363.5)
Male	12	11.2	107.1	(55.3-187.0)	Female	3	4.1	nc	(nc-nc)
Female	7	6.8	102.7	(41.2-211.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.6	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	7	9.6	73.3	(29.3-150.9)
Male	4	8.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	6.7	163.3	(81.4-292.2)	Female	16	19.6	81.5	(46.5-132.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	5.4	nc	(nc-nc)	Male	332	351.3	94.5	(84.6-105.2)
Female	2	1.9	nc	(nc-nc)	Female	337	322.6	104.5	(93.6-116.2)
<u>Lung and Bronchus</u>									
Male	56	49.5	113.2	(85.5-147.1)					
Female	59	44.6	132.4	(100.8-170.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	58.5	73.5	(53.2-99.0)	Male	25	33.7	74.1	(48.0-109.5)
Female	20	22.7	88.2	(53.8-136.2)	Female	29	29.0	100.0	(67.0-143.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	11.6	103.4	(53.4-180.6)	Male	7	8.9	79.0	(31.6-162.8)
Female	6	9.8	61.4	(22.4-133.8)	Female	11	7.2	153.3	(76.4-274.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.8	nc	(nc-nc)	Male	30	30.9	97.2	(65.5-138.7)
Female	225	221.4	101.6	(88.8-115.8)	Female	31	29.2	106.0	(72.0-150.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	10.2	88.1	(40.2-167.3)	Male	26	21.8	119.2	(77.9-174.7)
<u>Colon / Rectum</u>					Female	9	11.1	81.2	(37.0-154.1)
Male	67	87.5	76.5	(59.3-97.2)	<u>Ovary</u>				
Female	99	89.6	110.5	(89.8-134.5)	Female	29	24.3	119.6	(80.1-171.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	14.8	94.4	(51.6-158.4)	Male	17	16.5	103.0	(60.0-164.9)
Female	5	4.4	113.7	(36.6-265.4)	Female	18	19.2	93.7	(55.5-148.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	5.9	nc	(nc-nc)	Male	230	225.9	101.8	(89.1-115.9)
Female	2	4.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	15.0	100.1	(56.0-165.1)
Male	16	24.5	65.3	(37.3-106.0)	Female	14	9.7	144.8	(79.1-243.0)
Female	11	16.2	68.1	(33.9-121.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	11.0	54.3	(19.8-118.3)
Male	13	9.6	135.3	(72.0-231.4)	<u>Thyroid</u>				
Female	3	2.8	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
<u>Leukemia</u>					Female	22	24.8	88.9	(55.7-134.5)
Male	15	19.0	78.8	(44.1-130.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	16.1	87.2	(47.6-146.3)	Female	43	46.1	93.3	(67.5-125.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	11.8	109.8	(58.4-187.8)	Male	724	780.7	92.7	(86.1-99.7)
Female	10	4.6	219.3	(105.0-403.3)	Female	766	768.7	99.6	(92.7-107.0)
<u>Lung and Bronchus</u>									
Male	94	108.9	86.3	(69.8-105.6)					
Female	100	106.6	93.8	(76.3-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

316

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	11.3	53.2	(19.4-115.7)	Male	5	6.2	80.6	(26.0-188.0)
Female	5	4.4	113.4	(36.5-264.6)	Female	3	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.1	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
Female	24	41.5	57.8	(37.0-86.1)	Female	6	5.6	107.2	(39.1-233.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	1.8	279.5	(90.1-652.4)	Male	3	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.1	nc	(nc-nc)
Male	19	16.9	112.7	(67.8-176.0)	<u>Ovary</u>				
Female	12	17.8	67.6	(34.9-118.1)	Female	6	4.5	132.1	(48.2-287.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.9	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	3.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	49	43.4	112.9	(83.6-149.3)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.9	nc	(nc-nc)
Male	2	4.7	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.1	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.1	nc	(nc-nc)	Female	10	8.6	116.8	(55.9-214.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.3	nc	(nc-nc)	Male	144	148.1	97.2	(82.0-114.5)
Female	3	0.9	nc	(nc-nc)	Female	115	145.5	79.1	(65.3-94.9)
<u>Lung and Bronchus</u>									
Male	24	20.9	114.7	(73.5-170.7)					
Female	16	20.4	78.5	(44.8-127.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

317

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	26.3	79.7	(49.3-121.9)	Male	17	14.1	120.8	(70.3-193.5)
Female	8	9.5	83.9	(36.1-165.4)	Female	4	11.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.7	147.8	(59.2-304.5)	Male	3	4.0	nc	(nc-nc)
Female	5	4.0	126.0	(40.6-294.1)	Female	3	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	11	13.0	84.6	(42.2-151.3)
Female	87	93.8	92.8	(74.3-114.4)	Female	20	12.0	166.0	(101.3-256.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.0	175.1	(70.1-360.7)	Male	13	9.6	135.8	(72.2-232.2)
<u>Colon / Rectum</u>					Female	7	4.6	151.9	(60.8-312.9)
Male	50	39.1	128.0	(95.0-168.7)	<u>Ovary</u>				
Female	36	37.0	97.2	(68.1-134.6)	Female	8	10.1	79.1	(34.1-155.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	6.7	209.8	(114.6-352.1)	Male	8	7.4	107.9	(46.5-212.6)
Female	4	1.8	nc	(nc-nc)	Female	7	8.0	87.2	(34.9-179.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	121	104.7	115.5	(95.9-138.1)
Female	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.6	75.5	(24.3-176.2)
Male	22	10.9	202.7	(127.0-306.9)	Female	6	3.9	153.0	(55.9-333.1)
Female	6	6.8	87.9	(32.1-191.3)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.8	nc	(nc-nc)
Male	4	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	5	9.2	54.3	(17.5-126.7)
Male	12	8.0	149.1	(76.9-260.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.5	nc	(nc-nc)	Female	29	19.8	146.6	(98.1-210.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	5.2	133.5	(53.5-275.2)	Male	421	346.3	121.6	(110.2-133.8)
Female	5	1.9	264.8	(85.3-618.0)	Female	347	320.1	108.4	(97.3-120.4)
<u>Lung and Bronchus</u>									
Male	72	49.5	145.6	(113.9-183.4)					
Female	65	45.6	142.4	(109.9-181.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

318

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.4	93.0	(30.0-217.0)	Male	1	3.0	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	5	2.3	216.3	(69.7-504.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	15	18.3	81.8	(45.7-134.8)	Female	3	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	9	8.0	111.8	(51.0-212.3)	<u>Ovary</u>				
Female	11	6.9	159.7	(79.6-285.7)	Female	1	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.4	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	21.6	60.1	(32.0-102.7)
Female	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.4	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.0	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.3	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	57	72.1	79.1	(59.9-102.4)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	10.1	49.4	(15.9-115.3)					

Female 12 8.5 141.7 (73.1-247.5)

Female 65 61.6 105.5 (81.4-134.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

319

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	1	0.2	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)					

Lung and Bronchus

Male	1	1.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)

All Sites / Types

Male	9	11.2	80.2	(36.6-152.2)
Female	6	9.4	63.6	(23.2-138.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

320

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	0	0.1	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	1	1.1	nc	(nc-nc)	Male	5	8.3	60.6	(19.5-141.4)
Female	0	0.8	nc	(nc-nc)	Female	6	6.5	92.8	(33.9-202.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

321

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	37.2	126.3	(92.8-167.9)	Male	13	20.2	64.5	(34.3-110.3)
Female	20	16.1	124.4	(76.0-192.2)	Female	16	19.1	83.6	(47.8-135.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.6	90.4	(33.0-196.8)	Male	4	5.5	nc	(nc-nc)
Female	7	6.4	109.8	(44.0-226.3)	Female	3	5.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	16	18.7	85.5	(48.8-138.9)
Female	128	146.3	87.5	(73.0-104.1)	Female	22	20.3	108.4	(67.9-164.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.6	nc	(nc-nc)	Male	10	12.7	78.8	(37.7-144.8)
<u>Colon / Rectum</u>					Female	10	7.5	133.7	(64.0-245.9)
Male	44	54.7	80.5	(58.5-108.0)	<u>Ovary</u>				
Female	54	64.3	83.9	(63.0-109.5)	Female	16	16.1	99.3	(56.7-161.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	9.1	88.3	(38.0-173.9)	Male	13	10.3	126.8	(67.5-216.9)
Female	4	3.1	nc	(nc-nc)	Female	11	13.8	79.9	(39.8-142.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.1	nc	(nc-nc)	Male	122	136.9	89.1	(74.0-106.4)
Female	7	2.8	247.0	(99.0-509.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	9.4	127.2	(65.7-222.3)
Male	19	14.7	129.3	(77.8-201.9)	Female	4	7.0	nc	(nc-nc)
Female	10	11.0	91.1	(43.6-167.5)	<u>Testis</u>				
<u>Larynx</u>					Male	5	5.8	85.6	(27.6-199.7)
Male	3	5.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	1.9	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Leukemia</u>									
Male	5	11.5	43.6	(14.1-101.8)					

Female	14	11.1	126.7	(69.2-212.6)
<u>Liver and Intrahepatic Bile Ducts</u>				

Male	7	7.1	99.0	(39.7-204.0)
------	---	-----	------	--------------

Female	1	3.2	nc	(nc-nc)
--------	---	-----	----	---------

Lung and Bronchus

Male	69	68.3	101.1	(78.7-127.9)
------	----	------	-------	--------------

Female	60	73.8	81.3	(62.1-104.7)
--------	----	------	------	--------------

Female	18	15.5	115.9	(68.7-183.2)
<u>Uteri Corpus and Uterus, NOS</u>				

Female	31	30.0	103.4	(70.3-146.8)
--------	----	------	-------	--------------

All Sites / Types

Male	444	477.3	93.0	(84.6-102.1)
------	-----	-------	------	--------------

Female	479	522.5	91.7	(83.7-100.3)
--------	-----	-------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

322

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	16.3	98.3	(56.1-159.6)	Male	12	8.9	134.5	(69.4-235.0)
Female	3	5.4	nc	(nc-nc)	Female	7	7.0	100.6	(40.3-207.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.1	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	10	8.2	122.1	(58.4-224.5)
Female	63	59.2	106.5	(81.8-136.2)	Female	7	7.0	100.0	(40.1-206.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.8	nc	(nc-nc)
Male	16	24.4	65.7	(37.5-106.6)	<u>Ovary</u>				
Female	20	21.2	94.4	(57.6-145.8)	Female	11	6.3	175.9	(87.7-314.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.2	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.1	nc	(nc-nc)	Male	73	65.4	111.6	(87.5-140.4)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.1	nc	(nc-nc)
Male	3	6.9	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
Female	1	4.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.6	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

Leukemia

Male	4	5.1	nc	(nc-nc)
Female	5	3.8	130.1	(41.9-303.7)

Liver and Intrahepatic Bile Ducts

Male	4	3.4	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)

Lung and Bronchus

Male	13	30.7	42.3	(22.5-72.4)
Female	23	26.4	87.0	(55.2-130.6)

Thyroid

Male	3	1.8	nc	(nc-nc)
Female	11	5.8	188.5	(94.0-337.4)

Uteri Corpus and Uterus, NOS

Female	15	12.4	120.9	(67.6-199.5)
--------	----	------	-------	--------------

All Sites / Types

Male	191	216.6	88.2	(76.1-101.6)
Female	198	192.7	102.8	(89.0-118.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

323

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	20.1	109.6	(68.6-165.9)	Male	12	10.8	111.6	(57.6-194.9)
Female	11	8.0	137.2	(68.4-245.6)	Female	2	9.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	9	10.0	89.8	(41.0-170.4)
Female	71	72.5	98.0	(76.5-123.6)	Female	11	10.0	109.5	(54.6-195.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.1	nc	(nc-nc)	Male	7	7.1	98.6	(39.5-203.2)
<u>Colon / Rectum</u>					Female	6	3.7	162.5	(59.3-353.7)
Male	25	29.7	84.1	(54.4-124.1)	<u>Ovary</u>				
Female	36	32.5	110.8	(77.6-153.5)	Female	6	8.0	75.0	(27.4-163.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	5.0	161.0	(69.3-317.3)	Male	8	5.6	142.6	(61.4-281.0)
Female	3	1.6	nc	(nc-nc)	Female	6	6.9	86.8	(31.7-189.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	73	74.5	98.0	(76.8-123.3)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.1	97.9	(31.5-228.4)
Male	4	8.1	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
Female	7	5.4	128.5	(51.5-264.8)	<u>Testis</u>				
<u>Larynx</u>									

Male	5	3.2	156.9	(50.6-366.2)
Female	1	0.9	nc	(nc-nc)

Leukemia

Male	8	6.2	128.4	(55.3-253.0)
Female	6	5.6	106.9	(39.0-232.7)

Liver and Intrahepatic Bile Ducts

Male	2	3.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)

Lung and Bronchus

Male	43	36.7	117.1	(84.7-157.7)
Female	23	36.3	63.3	(40.1-95.0)

Male	2	2.5	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	3	2.2	nc	(nc-nc)
Female	2	7.1	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	15	14.9	100.7	(56.3-166.1)
--------	----	------	-------	--------------

All Sites / Types

Male	258	258.0	100.0	(88.2-113.0)
Female	240	258.8	92.7	(81.4-105.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

324

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	29.3	71.8	(44.4-109.7)	Male	34	16.0	212.8	(147.3-297.4)
Female	10	11.1	90.1	(43.1-165.7)	Female	20	13.7	145.5	(88.9-224.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.5	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	2	4.9	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	15	14.7	101.7	(56.9-167.8)
Female	116	111.3	104.2	(86.1-125.0)	Female	7	14.2	49.2	(19.7-101.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	4.8	nc	(nc-nc)	Male	15	11.1	135.5	(75.8-223.5)
<u>Colon / Rectum</u>					Female	8	5.5	146.3	(63.0-288.3)
Male	39	43.8	89.1	(63.3-121.8)	<u>Ovary</u>				
Female	44	44.1	99.7	(72.4-133.8)	Female	10	12.1	82.5	(39.5-151.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.5	nc	(nc-nc)	Male	2	8.3	nc	(nc-nc)
Female	5	2.2	231.6	(74.6-540.4)	Female	13	9.4	137.8	(73.3-235.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	2.0	300.7	(109.8-654.4)	Male	133	114.9	115.8	(96.9-137.2)
Female	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	7.4	nc	(nc-nc)
Male	15	12.3	121.9	(68.2-201.1)					

Female	5	8.0	62.4	(20.1-145.5)
--------	---	-----	------	--------------

Larynx

Male	1	4.9	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)

Leukemia

Male	12	9.2	130.7	(67.5-228.4)
Female	7	8.1	86.9	(34.8-179.1)

Liver and Intrahepatic Bile Ducts

Male	4	6.0	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)

Lung and Bronchus

Male	21	54.5	38.5	(23.8-58.9)
Female	21	52.1	40.3	(24.9-61.6)

Female	2	4.8	nc	(nc-nc)
--------	---	-----	----	---------

Testis

Male	1	3.1	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	4	3.3	nc	(nc-nc)
Female	13	11.5	112.9	(60.0-193.0)

Uteri Corpus and Uterus, NOS

Female	15	23.1	64.9	(36.3-107.0)
--------	----	------	------	--------------

All Sites / Types

Male	357	386.0	92.5	(83.1-102.6)
Female	333	379.6	87.7	(78.5-97.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

325

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.9	102.4	(33.0-238.9)	Male	3	2.4	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)	Female	6	1.8	329.2	(120.2-716.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	12	15.6	76.7	(39.6-134.0)	Female	3	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	0.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	6	7.1	84.4	(30.8-183.7)	<u>Ovary</u>				
Female	6	6.2	96.9	(35.4-210.9)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.2	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	28	18.3	153.4	(101.9-221.7)
Female	0	0.2	nc	(nc-nc)					

Kidney & Renal Pelvis

Male	0	1.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)

Larynx

Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Leukemia

Male	4	1.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	0.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)

Lung and Bronchus

Male	5	8.9	55.9	(18.0-130.5)
Female	7	7.8	90.1	(36.1-185.6)

Stomach

Male	3	1.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)

Testis

Male	0	0.4	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	6	3.3	179.8	(65.6-391.3)
--------	---	-----	-------	--------------

All Sites / Types

Male	70	61.1	114.5	(89.3-144.7)
Female	56	53.2	105.3	(79.5-136.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

326

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				

Male	0	0.1	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	1.5	nc	(nc-nc)	Male	6	11.7	51.3	(18.7-111.6)
Female	1	1.1	nc	(nc-nc)	Female	8	9.6	83.5	(35.9-164.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

327

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.1	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	19	17.1	111.0	(66.8-173.4)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	5	7.5	67.0	(21.6-156.4)	<u>Ovary</u>				
Female	15	6.9	218.7	(122.3-360.7)	Female	0	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)

Female	1	0.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	17	18.9	90.1	(52.5-144.3)
Female	0	0.4	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	1	2.0	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.0	nc	(nc-nc)					
Female	1	0.3	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	13	9.4	138.6	(73.7-237.0)	Male	64	65.0	98.4	(75.8-125.7)
Female	7	8.4	83.8	(33.6-172.6)	Female	61	59.2	103.0	(78.8-132.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

328

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	9.0	55.5	(17.9-129.6)	Male	1	5.2	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.8	104.9	(33.8-244.9)
Female	22	28.6	77.0	(48.2-116.6)	Female	5	3.7	133.4	(43.0-311.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	4	3.4	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	13.4	74.4	(35.6-136.9)					
Female	8	11.8	67.5	(29.1-133.1)	Female	4	3.1	nc	(nc-nc)

Esophagus

Male	4	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

Hodgkin Lymphoma

Male	1	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)

Kidney & Renal Pelvis

Male	6	3.8	159.9	(58.4-348.1)
Female	3	2.1	nc	(nc-nc)

Larynx

Male	2	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Leukemia

Male	1	2.9	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	1.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

Lung and Bronchus

Male	13	16.6	78.4	(41.7-134.1)
Female	13	13.9	93.8	(49.9-160.4)

Pancreas

Male	3	2.5	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)

Prostate

Male	29	33.6	86.4	(57.8-124.1)
------	----	------	------	--------------

Stomach

Male	0	2.3	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)

Testis

Male	1	1.6	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	1.1	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	5	5.9	85.5	(27.5-199.4)
--------	---	-----	------	--------------

All Sites / Types

Male	98	118.5	82.7	(67.2-100.8)
Female	86	98.5	87.3	(69.8-107.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

329

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.0	100.0	(45.6-189.9)	Male	3	4.8	nc	(nc-nc)
Female	7	3.5	202.0	(80.9-416.2)	Female	3	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.4	135.8	(49.6-295.6)
Female	22	32.0	68.9	(43.1-104.3)	Female	5	4.3	115.8	(37.3-270.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
					<u>Ovary</u>				

Male	12	13.3	90.2	(46.6-157.6)				
Female	11	13.9	79.1	(39.4-141.6)	Female	2	3.5	nc (nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>			
Male	3	2.2	nc	(nc-nc)	Male	5	2.5	198.5 (64.0-463.2)
Female	0	0.7	nc	(nc-nc)	Female	1	3.0	nc (nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>			
Male	1	0.6	nc	(nc-nc)	Male	31	34.1	91.0 (61.8-129.1)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>			
<u>Kidney & Renal Pelvis</u>					Male	1	2.3	nc (nc-nc)
Male	5	3.6	138.6	(44.7-323.5)	Female	1	1.5	nc (nc-nc)
Female	1	2.4	nc	(nc-nc)	<u>Testis</u>			
<u>Larynx</u>					Male	0	1.0	nc (nc-nc)
Male	3	1.4	nc	(nc-nc)	<u>Thyroid</u>			
Female	0	0.4	nc	(nc-nc)	Male	0	0.9	nc (nc-nc)
<u>Leukemia</u>					Female	6	3.0	203.2 (74.2-442.2)
Male	1	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>			
Female	2	2.4	nc	(nc-nc)	<u>All Sites / Types</u>			
<u>Liver and Intrahepatic Bile Ducts</u>					Female	4	6.7	nc (nc-nc)
Male	1	1.7	nc	(nc-nc)	Male	117	115.7	101.1 (83.6-121.2)
Female	0	0.7	nc	(nc-nc)	Female	104	112.4	92.5 (75.6-112.1)
<u>Lung and Bronchus</u>								
Male	20	16.5	120.9	(73.8-186.8)				
Female	23	16.0	144.0	(91.3-216.1)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

330

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.1	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.1	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	9	20.7	43.6	(19.9-82.7)	Female	0	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	1	1.8	nc	(nc-nc)

Female	1	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	7.4	107.6	(46.3-212.0)					
Female	11	10.8	101.9	(50.8-182.4)	Female	1	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.2	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	17	18.1	93.9	(54.7-150.3)
Female	0	0.3	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	1	1.9	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	5	1.6	318.0	(102.5-742.0)	Female	0	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.0	nc	(nc-nc)					
Female	1	0.5	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	9	8.8	101.9	(46.5-193.4)	Male	60	63.2	94.9	(72.5-122.2)
Female	4	10.5	nc	(nc-nc)	Female	44	77.0	57.1	(41.5-76.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

331

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.8	131.0	(42.2-305.7)	Male	1	2.5	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	7	1.9	363.4	(145.6-748.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	12	15.8	76.0	(39.2-132.8)	Female	1	1.7	nc	(nc-nc)

Cervix Uteri

Female	2	0.8	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	5	6.0	83.6	(26.9-195.1)
Female	6	4.8	124.5	(45.5-271.0)

Esophagus

Male	1	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)

Hodgkin Lymphoma

Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Kidney & Renal Pelvis

Male	0	1.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)

Larynx

Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Leukemia

Male	0	1.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Lung and Bronchus

Male	4	7.3	nc	(nc-nc)
Female	7	6.1	114.3	(45.8-235.5)

Oral Cavity & Pharynx

Male	0	1.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)

Ovary

Female	2	1.6	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	1.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)

Prostate

Male	26	16.5	157.3	(102.7-230.5)
------	----	------	-------	---------------

Stomach

Male	0	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Testis

Male	1	0.6	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	0.6	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	1	3.2	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	46	55.0	83.7	(61.3-111.6)
Female	48	48.5	99.0	(73.0-131.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

332

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	33.8	136.0	(99.5-181.4)	Male	15	18.2	82.2	(46.0-135.6)
Female	13	12.4	104.8	(55.7-179.2)	Female	15	14.8	101.6	(56.8-167.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.2	162.1	(77.6-298.1)	Male	3	5.1	nc	(nc-nc)
Female	1	5.1	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	0	1.0	nc	(nc-nc)	Male	11	16.9	65.0	(32.4-116.3)
Female	125	119.3	104.7	(87.2-124.8)	Female	16	15.7	101.6	(58.0-165.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.1	nc	(nc-nc)	Male	11	12.1	90.8	(45.3-162.6)
<u>Colon / Rectum</u>					Female	3	5.9	nc	(nc-nc)
Male	46	50.1	91.9	(67.3-122.6)	<u>Ovary</u>				
Female	41	49.0	83.6	(60.0-113.4)	Female	12	13.0	92.4	(47.7-161.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	8.4	118.4	(56.7-217.7)	Male	6	9.5	63.5	(23.2-138.2)
Female	6	2.4	248.8	(90.8-541.5)	Female	8	10.5	75.9	(32.7-149.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.5	nc	(nc-nc)	Male	117	129.6	90.3	(74.7-108.2)
Female	3	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	8.6	128.6	(64.1-230.1)
Male	15	13.8	109.0	(61.0-179.8)	Female	3	5.3	nc	(nc-nc)
Female	8	8.8	91.0	(39.2-179.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.3	nc	(nc-nc)
Male	5	5.5	91.5	(29.5-213.6)	<u>Thyroid</u>				
Female	2	1.5	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	9	11.9	75.6	(34.5-143.5)
Male	11	10.5	105.1	(52.4-188.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	8.6	nc	(nc-nc)	Female	23	24.9	92.5	(58.6-138.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.7	nc	(nc-nc)	Male	417	440.2	94.7	(85.9-104.3)
Female	5	2.5	202.1	(65.1-471.6)	Female	399	413.4	96.5	(87.3-106.5)
<u>Lung and Bronchus</u>									
Male	61	62.7	97.2	(74.4-124.9)					
Female	53	58.5	90.6	(67.8-118.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

333

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)

Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	5	7.2	69.8	(22.5-162.9)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	7.9	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	18	27.2	66.1	(39.1-104.4)
Female	0	0.1	nc	(nc-nc)	Female	20	23.5	85.1	(51.9-131.4)
<u>Lung and Bronchus</u>									
Male	3	3.9	nc	(nc-nc)					
Female	6	3.3	181.1	(66.1-394.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

334

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.6	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)

Brain and Other Nervous System

Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Breast

Male	0	0.1	nc	(nc-nc)
Female	11	10.5	105.2	(52.5-188.3)

Cervix Uteri

Female	0	0.5	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	2	4.0	nc	(nc-nc)
Female	5	3.3	152.9	(49.3-356.8)

Esophagus

Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Hodgkin Lymphoma

Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Kidney & Renal Pelvis

Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)

Larynx

Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Leukemia

Male	1	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Lung and Bronchus

Male	2	4.9	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)

Multiple Myeloma

Male	1	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)

Non-Hodgkin Lymphoma

Male	2	1.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)

Oral Cavity & Pharynx

Male	1	1.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)

Ovary

Female	0	1.1	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)

Prostate

Male	19	10.7	177.8	(107.0-277.6)
------	----	------	-------	---------------

Stomach

Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Testis

Male	1	0.4	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	0.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	1	2.1	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	38	36.2	104.9	(74.2-144.0)
Female	28	32.3	86.6	(57.5-125.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>				<u>Melanoma of Skin</u>			

Male	19	16.6	114.1	(68.7-178.2)	Male	10	10.1	98.8	(47.3-181.8)
Female	1	6.5	nc	(nc-nc)	Female	14	8.6	162.0	(88.5-271.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.6	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	9	9.2	98.2	(44.8-186.4)
Female	63	66.7	94.5	(72.6-120.9)	Female	6	8.5	70.9	(25.9-154.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.2	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	6	3.2	185.9	(67.9-404.6)
Male	17	25.3	67.3	(39.2-107.7)	<u>Ovary</u>				
Female	19	26.8	70.9	(42.7-110.8)	Female	11	7.2	153.4	(76.5-274.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.3	nc	(nc-nc)	Male	8	4.7	168.5	(72.5-331.9)
Female	1	1.3	nc	(nc-nc)	Female	0	5.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	57	63.2	90.2	(68.3-116.9)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.3	115.1	(37.1-268.7)
Male	7	7.3	96.1	(38.5-197.9)	Female	1	3.0	nc	(nc-nc)
Female	2	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.9	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.6	nc	(nc-nc)
Male	7	5.7	123.9	(49.6-255.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.9	nc	(nc-nc)	Female	14	13.2	106.1	(57.9-178.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.6	nc	(nc-nc)	Male	195	224.1	87.0	(75.2-100.1)
Female	1	1.4	nc	(nc-nc)	Female	191	226.3	84.4	(72.9-97.3)
<u>Lung and Bronchus</u>									
Male	20	30.4	65.8	(40.2-101.7)					
Female	23	29.2	78.8	(49.9-118.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	42.1	104.4	(75.9-140.2)	Male	16	23.5	68.0	(38.8-110.4)
Female	19	15.9	119.5	(71.9-186.7)	Female	18	19.7	91.5	(54.2-144.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.2	73.1	(26.7-159.0)	Male	8	6.4	125.7	(54.1-247.6)
Female	5	6.9	72.8	(23.5-170.0)	Female	1	5.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	20	21.8	91.8	(56.1-141.8)
Female	142	155.8	91.1	(76.8-107.4)	Female	27	20.4	132.3	(87.2-192.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.9	86.7	(31.7-188.7)	Male	14	15.7	89.0	(48.6-149.3)
<u>Colon / Rectum</u>					Female	6	7.7	77.7	(28.4-169.2)
Male	66	62.9	104.9	(81.1-133.4)	<u>Ovary</u>				
Female	63	63.4	99.3	(76.3-127.1)	Female	16	17.0	94.0	(53.7-152.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	10.6	131.7	(72.0-221.0)	Male	12	11.9	100.9	(52.1-176.3)
Female	5	3.1	161.4	(52.0-376.6)	Female	13	13.5	96.0	(51.1-164.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	3.6	nc	(nc-nc)	Male	132	160.2	82.4	(69.0-97.7)
Female	1	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	10.7	121.0	(64.4-206.9)
Male	22	17.5	125.7	(78.8-190.3)	Female	4	6.9	nc	(nc-nc)
Female	6	11.4	52.8	(19.3-115.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	6.1	nc	(nc-nc)
Male	4	6.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	2.0	nc	(nc-nc)	Male	0	5.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	16.4	67.0	(33.4-119.9)
Male	8	13.5	59.1	(25.5-116.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	11.4	70.2	(30.2-138.3)	Female	32	32.1	99.7	(68.2-140.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.5	58.5	(18.9-136.6)	Male	498	553.8	89.9	(82.2-98.2)
Female	2	3.2	nc	(nc-nc)	Female	504	537.8	93.7	(85.7-102.3)
<u>Lung and Bronchus</u>									
Male	82	77.7	105.5	(83.9-131.0)					
Female	76	74.3	102.3	(80.6-128.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	15.2	105.6	(60.3-171.4)	Male	9	10.5	85.8	(39.1-162.8)
Female	6	5.3	112.8	(41.2-245.5)	Female	15	8.9	169.0	(94.5-278.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.0	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	11	9.2	119.8	(59.7-214.4)
Female	81	69.0	117.4	(93.2-145.9)	Female	7	7.5	93.3	(37.4-192.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.6	138.9	(44.8-324.2)	Male	1	7.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	3.1	nc	(nc-nc)
Male	31	24.1	128.8	(87.5-182.8)	<u>Ovary</u>				
Female	20	21.1	94.9	(57.9-146.6)	Female	15	7.1	210.5	(117.7-347.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.3	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	63	66.5	94.7	(72.7-121.1)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.0	nc	(nc-nc)
Male	10	7.8	128.1	(61.3-235.5)	Female	1	2.2	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.1	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	11	8.7	126.2	(62.9-225.8)
Male	3	5.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.4	113.2	(36.5-264.2)	Female	10	13.8	72.6	(34.7-133.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.8	nc	(nc-nc)	Male	214	225.3	95.0	(82.7-108.6)
Female	1	1.1	nc	(nc-nc)	Female	236	213.5	110.5	(96.9-125.6)
<u>Lung and Bronchus</u>									
Male	32	29.5	108.3	(74.1-153.0)					
Female	30	26.0	115.2	(77.7-164.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
Female	8	5.9	135.0	(58.1-266.1)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.3	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	6.3	110.9	(44.4-228.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.7	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.3	nc	(nc-nc)	Male	21	20.8	100.8	(62.4-154.1)
Female	0	0.1	nc	(nc-nc)	Female	16	18.0	89.1	(50.9-144.8)
<u>Lung and Bronchus</u>									
Male	4	2.8	nc	(nc-nc)					
Female	1	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

339

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.0	128.1	(58.4-243.2)	Male	2	4.3	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	24	26.6	90.1	(57.7-134.1)	Female	0	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	17	10.8	157.3	(91.6-251.8)	<u>Ovary</u>				
Female	10	8.9	112.0	(53.6-205.9)	Female	4	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.9	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	30	28.3	106.1	(71.6-151.4)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.0	479.6	(154.6-1119.3)
Male	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.0	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.7	nc	(nc-nc)	Female	9	5.4	166.9	(76.1-316.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)	Male	95	96.8	98.1	(79.4-119.9)
Female	0	0.5	nc	(nc-nc)	Female	80	85.0	94.2	(74.7-117.2)
<u>Lung and Bronchus</u>									
Male	7	13.2	53.0	(21.2-109.1)					
Female	9	11.1	81.2	(37.1-154.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

340

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	16.5	48.6	(20.9-95.7)	Male	11	8.5	129.7	(64.7-232.1)
Female	3	5.3	nc	(nc-nc)	Female	12	6.2	194.9	(100.6-340.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	5	2.2	227.4	(73.3-530.6)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	7.9	151.8	(78.4-265.2)
Female	61	51.9	117.4	(89.8-150.8)	Female	6	6.6	90.6	(33.1-197.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.2	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.5	nc	(nc-nc)
Male	20	24.3	82.3	(50.2-127.1)	<u>Ovary</u>				
Female	11	21.2	51.8	(25.8-92.7)	Female	8	5.6	141.8	(61.1-279.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.1	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	75	62.7	119.5	(94.0-149.8)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.2	nc	(nc-nc)
Male	6	6.6	91.3	(33.3-198.8)	Female	3	2.3	nc	(nc-nc)
Female	5	3.7	134.2	(43.2-313.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.2	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	13	4.9	264.1	(140.5-451.6)
Male	7	4.9	143.0	(57.3-294.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.7	161.3	(58.9-351.0)	Female	9	10.9	82.9	(37.8-157.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.2	nc	(nc-nc)	Male	194	210.3	92.2	(79.7-106.2)
Female	1	1.1	nc	(nc-nc)	Female	178	177.2	100.5	(86.3-116.4)
<u>Lung and Bronchus</u>									
Male	14	30.0	46.7	(25.5-78.3)					
Female	15	24.3	61.8	(34.6-102.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

341

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	18.2	126.0	(79.9-189.1)	Male	10	10.2	97.9	(46.9-180.1)
Female	3	6.1	nc	(nc-nc)	Female	6	7.8	77.4	(28.3-168.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.4	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	5	1.9	259.1	(83.5-604.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	5	9.3	53.7	(17.3-125.3)
Female	78	64.3	121.2	(95.8-151.3)	Female	7	7.8	89.6	(35.9-184.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.8	nc	(nc-nc)	Male	6	7.2	83.5	(30.5-181.7)
<u>Colon / Rectum</u>					Female	2	3.1	nc	(nc-nc)
Male	19	27.5	69.0	(41.5-107.8)	<u>Ovary</u>				
Female	17	23.5	72.4	(42.2-116.0)	Female	7	6.9	102.0	(40.9-210.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.8	nc	(nc-nc)	Male	1	5.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.3	nc	(nc-nc)	Male	78	74.7	104.4	(82.6-130.3)
Female	3	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.6	nc	(nc-nc)
Male	10	7.9	126.9	(60.8-233.5)	Female	2	2.5	nc	(nc-nc)
Female	5	4.5	110.8	(35.7-258.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.2	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	12	6.5	184.6	(95.3-322.6)
Male	9	5.6	159.6	(72.8-303.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.2	144.1	(52.6-313.6)	Female	16	13.7	116.9	(66.8-189.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.8	nc	(nc-nc)	Male	251	246.0	102.0	(89.8-115.5)
Female	0	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	45	34.5	130.3	(95.0-174.3)					

Female 30 29.5 101.6 (68.6-145.1)

Female 224 212.4 105.5 (92.1-120.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

342

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	20.5	107.5	(67.4-162.8)	Male	8	10.3	77.8	(33.5-153.4)
Female	5	7.5	66.8	(21.5-155.8)	Female	19	8.1	235.4	(141.7-367.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.4	147.6	(47.6-344.5)	Male	2	3.0	nc	(nc-nc)
Female	5	2.9	172.4	(55.6-402.3)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	9	9.7	92.7	(42.3-176.1)
Female	72	67.5	106.6	(83.4-134.3)	Female	10	9.3	108.0	(51.7-198.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.8	nc	(nc-nc)	Male	7	6.8	103.3	(41.4-212.9)
<u>Colon / Rectum</u>					Female	2	3.4	nc	(nc-nc)
Male	26	29.8	87.2	(56.9-127.7)	<u>Ovary</u>				
Female	33	30.4	108.5	(74.6-152.3)	Female	5	7.4	67.5	(21.7-157.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.9	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	9	6.5	139.2	(63.5-264.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	88	73.4	119.9	(96.2-147.8)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.2	nc	(nc-nc)
Male	6	7.8	77.1	(28.1-167.7)	Female	0	3.4	nc	(nc-nc)
Female	8	5.1	158.0	(68.0-311.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.7	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.1	115.6	(46.3-238.2)
Male	8	6.1	131.9	(56.8-259.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.2	134.9	(54.0-277.9)	Female	12	13.9	86.5	(44.6-151.1)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	3	3.8	nc	(nc-nc)					
Female	0	1.5	nc	(nc-nc)					

Lung and Bronchus

Male	26	36.6	71.1	(46.4-104.1)
Female	24	33.8	71.0	(45.5-105.7)

All Sites / Types

Male	243	253.8	95.7	(84.1-108.6)
Female	246	239.7	102.6	(90.2-116.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

343

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	83	61.1	135.9	(108.2-168.5)	Male	37	33.9	109.2	(76.9-150.6)
Female	21	24.6	85.5	(52.9-130.7)	Female	38	29.9	127.1	(89.9-174.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.6	86.5	(41.4-159.0)	Male	9	9.2	97.7	(44.6-185.5)
Female	8	10.3	77.8	(33.5-153.4)	Female	3	7.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	32	31.1	102.9	(70.3-145.2)
Female	253	240.8	105.1	(92.5-118.9)	Female	21	31.2	67.2	(41.6-102.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	10.6	47.3	(15.2-110.3)	Male	27	22.7	118.9	(78.4-173.1)
<u>Colon / Rectum</u>					Female	6	11.9	50.6	(18.5-110.1)
Male	94	91.1	103.2	(83.4-126.3)	<u>Ovary</u>				
Female	82	96.5	85.0	(67.6-105.5)	Female	26	26.1	99.8	(65.2-146.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	15.6	96.4	(53.9-159.0)	Male	18	17.3	104.3	(61.8-164.8)
Female	2	4.8	nc	(nc-nc)	Female	15	20.8	72.3	(40.4-119.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	4.7	nc	(nc-nc)	Male	195	240.8	81.0	(70.0-93.2)
Female	5	4.1	122.5	(39.5-285.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	15.4	64.8	(31.0-119.1)
Male	35	25.7	136.3	(94.9-189.5)	Female	11	10.3	106.3	(53.0-190.2)
Female	29	17.6	165.2	(110.6-237.3)	<u>Testis</u>				
<u>Larynx</u>					Male	9	8.2	109.3	(49.9-207.5)
Male	9	10.1	88.8	(40.5-168.6)	<u>Thyroid</u>				
Female	3	3.1	nc	(nc-nc)	Male	8	7.2	111.6	(48.1-219.9)
<u>Leukemia</u>					Female	36	24.5	147.1	(103.0-203.7)
Male	16	19.2	83.3	(47.6-135.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	17.0	88.0	(49.2-145.2)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	8	12.4	64.5	(27.8-127.2)					
Female	8	4.9	163.0	(70.2-321.3)	Female	47	50.1	93.8	(68.9-124.8)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	125	114.8	108.8	(90.6-129.7)	Male	812	810.2	100.2	(93.4-107.4)
Female	142	116.3	122.1	(102.8-143.9)	Female	822	826.0	99.5	(92.8-106.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

344

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	3	6.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	5	2.3	218.7	(70.5-510.3)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	7.2	111.9	(48.2-220.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	2	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>									
Male	0	0.6	nc	(nc-nc)					

Female	0	0.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	1	3.4	nc	(nc-nc)	Male	23	24.7	93.2	(59.0-139.8)
Female	1	2.8	nc	(nc-nc)	Female	17	21.0	81.0	(47.2-129.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

345

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	11.7	119.5	(65.3-200.4)	Male	5	7.4	67.8	(21.9-158.3)
Female	5	4.3	116.1	(37.4-270.9)	Female	9	6.4	141.3	(64.5-268.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.7	186.1	(60.0-434.2)	Male	1	1.8	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	6.6	151.7	(72.6-278.9)
Female	45	48.9	92.0	(67.1-123.1)	Female	3	5.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.4	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.3	nc	(nc-nc)
Male	16	18.1	88.5	(50.5-143.7)	<u>Ovary</u>				
Female	19	16.9	112.5	(67.7-175.7)	Female	1	5.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	3.2	252.9	(108.9-498.3)	Male	5	3.4	145.6	(46.9-339.9)
Female	2	0.8	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	41	48.8	83.9	(60.2-113.9)
Female	4	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.0	nc	(nc-nc)
Male	5	5.5	91.6	(29.5-213.7)	Female	1	1.8	nc	(nc-nc)
Female	7	3.3	209.0	(83.7-430.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.3	nc	(nc-nc)
Male	5	2.1	239.0	(77.0-557.7)					
Female	0	0.6	nc	(nc-nc)					

Leukemia

Male	3	4.1	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	2.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)

Lung and Bronchus

Male	24	22.4	107.3	(68.8-159.7)
Female	32	21.0	152.4	(104.2-215.1)

Thyroid

Male	2	1.7	nc	(nc-nc)
Female	6	5.9	101.7	(37.1-221.4)

Uteri Corpus and Uterus, NOS

Female	7	10.0	69.7	(27.9-143.6)
--------	---	------	------	--------------

All Sites / Types

Male	169	165.6	102.1	(87.2-118.7)
Female	170	159.6	106.5	(91.1-123.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

346

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	18.4	59.6	(29.7-106.7)	Male	11	9.8	112.1	(55.9-200.7)
Female	5	6.6	75.9	(24.4-177.0)	Female	8	7.7	104.3	(44.9-205.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.3	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	7	2.7	260.2	(104.3-536.2)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	9.1	131.6	(67.9-229.9)
Female	86	64.8	132.7	(106.2-163.9)	Female	16	8.3	193.4	(110.5-314.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	1	6.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	3.2	nc	(nc-nc)
Male	25	27.5	91.0	(58.9-134.4)	<u>Ovary</u>				
Female	33	26.2	126.0	(86.7-177.0)	Female	12	7.0	171.9	(88.7-300.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	4.7	nc	(nc-nc)	Male	0	5.2	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	5	5.6	89.1	(28.7-208.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	84	72.1	116.5	(92.9-144.3)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.6	nc	(nc-nc)
Male	2	7.6	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
Female	4	4.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>									

Male	2	3.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)

Leukemia

Male	3	5.6	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	3.7	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)

Lung and Bronchus

Male	17	34.4	49.4	(28.7-79.1)
Female	14	30.8	45.4	(24.8-76.2)

Male	1	1.7	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	4	1.9	nc	(nc-nc)
Female	2	6.1	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	11	13.5	81.6	(40.7-146.0)
--------	----	------	------	--------------

All Sites / Types

Male	195	240.8	81.0	(70.0-93.2)
Female	234	220.5	106.1	(93.0-120.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

347

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.1	163.5	(52.7-381.5)	Male	1	1.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	19	10.7	177.8	(107.0-277.7)	Female	1	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	10	4.6	217.7	(104.2-400.3)	<u>Ovary</u>				
Female	1	3.6	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	11.8	101.9	(52.6-178.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)					

Female	2	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	5	5.6	89.3	(28.8-208.5)	Male	50	40.1	124.6	(92.4-164.2)
Female	2	4.5	nc	(nc-nc)	Female	34	34.0	99.9	(69.2-139.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

348

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.8	110.8	(57.2-193.6)	Male	6	5.3	112.8	(41.2-245.5)
Female	3	4.6	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
Female	50	37.7	132.7	(98.5-175.0)	Female	6	5.6	106.7	(39.0-232.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
					Female	2	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	15.7	89.2	(48.7-149.7)					
Female	16	19.2	83.5	(47.7-135.6)	Female	2	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.6	nc	(nc-nc)	Male	0	3.0	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	69	38.2	180.6	(140.5-228.6)
Female	1	0.7	nc	(nc-nc)					

Kidney & Renal Pelvis

Male	2	4.0	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)

Larynx

Male	2	1.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)

Leukemia

Male	7	3.2	217.4	(87.1-448.0)
Female	5	3.1	158.8	(51.2-370.7)

Liver and Intrahepatic Bile Ducts

Male	0	1.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)

Lung and Bronchus

Male	14	19.3	72.6	(39.7-121.9)
Female	20	20.2	99.1	(60.5-153.1)

Stomach

Male	6	2.7	219.4	(80.1-477.5)
Female	2	2.2	nc	(nc-nc)

Testis

Male	0	1.2	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	1.0	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	9	7.9	114.5	(52.2-217.3)
--------	---	-----	-------	--------------

All Sites / Types

Male	151	133.3	113.3	(95.9-132.8)
Female	140	141.4	99.0	(83.3-116.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

349

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	19.4	72.0	(39.3-120.8)	Male	11	11.9	92.5	(46.1-165.6)
Female	4	7.2	nc	(nc-nc)	Female	5	10.0	50.0	(16.1-116.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.3	116.0	(37.4-270.6)	Male	3	3.0	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	10.7	74.9	(32.3-147.6)
Female	89	78.0	114.1	(91.6-140.4)	Female	11	9.5	116.2	(57.9-208.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.8	nc	(nc-nc)	Male	9	8.1	110.7	(50.5-210.1)
<u>Colon / Rectum</u>					Female	6	3.7	161.9	(59.1-352.4)
Male	30	29.7	100.9	(68.1-144.0)	<u>Ovary</u>				
Female	21	28.1	74.6	(46.2-114.1)	Female	8	8.3	96.4	(41.5-190.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.2	115.3	(42.1-251.0)	Male	2	5.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	6	6.0	99.9	(36.5-217.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				

Male	2	1.8	nc	(nc-nc)	Male	97	80.9	119.9	(97.2-146.2)
Female	3	1.5	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	10	8.9	112.0	(53.6-205.9)	Male	5	5.0	100.0	(32.2-233.3)
Female	4	5.4	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	3.4	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	9	6.6	135.6	(61.9-257.5)	Male	3	2.8	nc	(nc-nc)
Female	10	5.4	186.1	(89.1-342.4)	Female	11	9.0	122.7	(61.2-219.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	4.3	nc	(nc-nc)					
Female	0	1.5	nc	(nc-nc)	Female	17	16.0	106.0	(61.7-169.7)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	41	37.2	110.1	(79.0-149.4)	Male	284	271.8	104.5	(92.7-117.4)
Female	47	34.4	136.8	(100.5-181.9)	Female	271	257.7	105.1	(93.0-118.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

350

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.5	93.7	(40.3-184.6)	Male	1	5.2	nc	(nc-nc)
Female	5	3.1	162.8	(52.5-380.0)	Female	4	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	27	33.1	81.6	(53.7-118.7)	Female	3	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	5	3.5	141.1	(45.5-329.2)
Female	2	1.6	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	13.1	107.2	(58.6-179.9)					
Female	10	12.1	82.9	(39.7-152.4)	Female	8	3.5	225.4	(97.0-444.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.3	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)

Female	0	0.6	nc	(nc-nc)
--------	---	-----	----	---------

Hodgkin Lymphoma

Male	0	0.8	nc	(nc-nc)
------	---	-----	----	---------

Female	1	0.7	nc	(nc-nc)
--------	---	-----	----	---------

Kidney & Renal Pelvis

Male	5	3.9	128.2	(41.3-299.1)
------	---	-----	-------	--------------

Female	3	2.3	nc	(nc-nc)
--------	---	-----	----	---------

Larynx

Male	1	1.5	nc	(nc-nc)
------	---	-----	----	---------

Female	1	0.4	nc	(nc-nc)
--------	---	-----	----	---------

Leukemia

Male	5	2.9	170.1	(54.8-397.0)
------	---	-----	-------	--------------

Female	0	2.3	nc	(nc-nc)
--------	---	-----	----	---------

Liver and Intrahepatic Bile Ducts

Male	3	1.9	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.6	nc	(nc-nc)
--------	---	-----	----	---------

Lung and Bronchus

Male	14	16.2	86.6	(47.3-145.3)
------	----	------	------	--------------

Female	23	14.7	156.2	(99.0-234.4)
--------	----	------	-------	--------------

Female	3	2.6	nc	(nc-nc)
--------	---	-----	----	---------

Prostate

Male	31	34.9	88.7	(60.3-126.0)
------	----	------	------	--------------

Stomach

Male	2	2.2	nc	(nc-nc)
------	---	-----	----	---------

Female	1	1.3	nc	(nc-nc)
--------	---	-----	----	---------

Testis

Male	2	1.5	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	1.2	nc	(nc-nc)
------	---	-----	----	---------

Female	1	3.9	nc	(nc-nc)
--------	---	-----	----	---------

Uteri Corpus and Uterus, NOS

Female	7	6.8	103.4	(41.4-213.1)
--------	---	-----	-------	--------------

All Sites / Types

Male	108	118.7	91.0	(74.6-109.8)
------	-----	-------	------	--------------

Female	108	110.3	97.9	(80.3-118.3)
--------	-----	-------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

351

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
--	------------	------------	------------	---------------

Bladder, Urinary

Male	24	27.1	88.4	(56.6-131.6)
------	----	------	------	--------------

Female	7	10.6	65.8	(26.3-135.5)
--------	---	------	------	--------------

Brain and Other Nervous System

Male	12	4.8	248.0	(128.0-433.3)
------	----	-----	-------	---------------

Female	3	4.2	nc	(nc-nc)
--------	---	-----	----	---------

Breast

Male	3	0.8	nc	(nc-nc)
------	---	-----	----	---------

Female	111	100.0	110.9	(91.3-133.6)
--------	-----	-------	-------	--------------

Cervix Uteri

Female	2	4.2	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	26	40.2	64.7	(42.3-94.8)
------	----	------	------	-------------

Female	38	43.2	88.0	(62.3-120.8)
--------	----	------	------	--------------

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
--	------------	------------	------------	---------------

Melanoma of Skin

Male	19	14.4	131.7	(79.3-205.8)
------	----	------	-------	--------------

Female	12	12.1	99.5	(51.3-173.7)
--------	----	------	------	--------------

Multiple Myeloma

Male	4	4.1	nc	(nc-nc)
------	---	-----	----	---------

Female	5	3.4	149.2	(48.1-348.2)
--------	---	-----	-------	--------------

Non-Hodgkin Lymphoma

Male	12	13.3	89.9	(46.4-157.1)
------	----	------	------	--------------

Female	15	13.3	113.0	(63.2-186.4)
--------	----	------	-------	--------------

Oral Cavity & Pharynx

Male	8	9.8	81.7	(35.2-161.0)
------	---	-----	------	--------------

Female	9	5.0	180.6	(82.4-342.8)
--------	---	-----	-------	--------------

Ovary

Female	10	10.9	91.7	(43.9-168.6)
--------	----	------	------	--------------

Esophagus

Male	3	6.8	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)

Hodgkin Lymphoma

Male	2	1.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)

Kidney & Renal Pelvis

Male	12	11.1	108.5	(56.0-189.6)
Female	8	7.3	109.4	(47.1-215.7)

Larynx

Male	4	4.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)

Leukemia

Male	7	8.3	84.7	(33.9-174.6)
Female	8	7.4	107.7	(46.4-212.3)

Liver and Intrahepatic Bile Ducts

Male	4	5.4	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)

Lung and Bronchus

Male	34	50.0	67.9	(47.0-94.9)
Female	36	48.2	74.7	(52.3-103.4)

Pancreas

Male	5	7.6	65.6	(21.1-153.2)
Female	5	9.1	54.7	(17.6-127.5)

Prostate

Male	132	104.3	126.6	(105.9-150.2)
------	-----	-------	-------	---------------

Stomach

Male	4	6.9	nc	(nc-nc)
Female	5	4.8	105.0	(33.8-245.1)

Testis

Male	2	2.7	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	6	2.9	210.1	(76.7-457.4)
Female	10	9.4	106.4	(51.0-195.8)

Uteri Corpus and Uterus, NOS

Female	27	20.7	130.4	(85.9-189.8)
--------	----	------	-------	--------------

All Sites / Types

Male	344	351.3	97.9	(87.9-108.9)
Female	335	348.7	96.1	(86.1-106.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

352

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.9	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	3.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
					<u>Ovary</u>				

Male	0	1.4	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	12.6	79.3	(38.0-145.9)
Female	0	0.1	nc	(nc-nc)	Female	5	10.6	47.1	(15.2-109.9)
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	1	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

353

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	21.5	111.6	(71.5-166.0)	Male	15	11.8	127.0	(71.0-209.5)
Female	9	8.5	105.5	(48.2-200.4)	Female	16	10.2	156.1	(89.2-253.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.9	153.7	(56.1-334.5)	Male	3	3.2	nc	(nc-nc)
Female	6	3.5	172.6	(63.0-375.6)	Female	4	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	6	10.9	55.2	(20.2-120.2)
Female	79	81.1	97.4	(77.1-121.4)	Female	11	10.8	101.7	(50.7-182.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	2	7.8	nc	(nc-nc)

Female	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>				
Male	40	32.0	125.0	(89.3-170.2)
Female	46	34.1	134.9	(98.7-179.9)
<u>Esophagus</u>				
Male	5	5.4	92.7	(29.9-216.4)
Female	0	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>				
Male	1	1.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>				
Male	22	8.8	249.1	(156.1-377.2)
Female	4	6.0	nc	(nc-nc)
<u>Larynx</u>				
Male	3	3.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)
<u>Leukemia</u>				
Male	8	6.6	120.7	(52.0-237.8)
Female	5	5.9	84.3	(27.2-196.7)
<u>Liver and Intrahepatic Bile Ducts</u>				
Male	6	4.3	140.6	(51.4-306.1)
Female	1	1.7	nc	(nc-nc)
<u>Lung and Bronchus</u>				
Male	39	39.6	98.4	(70.0-134.5)
Female	58	39.5	146.9	(111.5-189.9)

Female	2	4.0	nc	(nc-nc)
<u>Ovary</u>				
Female	17	8.8	192.4	(112.0-308.1)
<u>Pancreas</u>				
Male	5	6.0	82.7	(26.6-193.0)
Female	7	7.3	96.1	(38.5-198.0)
<u>Prostate</u>				
Male	86	81.9	105.1	(84.0-129.8)
<u>Stomach</u>				
Male	2	5.5	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)
<u>Testis</u>				
Male	3	2.8	nc	(nc-nc)
<u>Thyroid</u>				
Male	1	2.5	nc	(nc-nc)
Female	7	8.3	83.9	(33.6-172.9)
<u>Uteri Corpus and Uterus, NOS</u>				
Female	19	16.6	114.2	(68.7-178.4)
<u>All Sites / Types</u>				
Male	297	280.2	106.0	(94.3-118.7)
Female	321	282.8	113.5	(101.4-126.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

354

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	42.9	81.7	(56.9-113.6)	Male	35	23.9	146.6	(102.1-203.9)
Female	20	16.1	124.0	(75.7-191.5)	Female	17	19.8	85.8	(49.9-137.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	8.1	111.1	(50.7-211.0)	Male	8	6.5	123.9	(53.4-244.2)
Female	9	6.8	132.6	(60.5-251.6)	Female	7	5.1	137.7	(55.2-283.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	30	21.9	137.2	(92.5-195.8)
Female	182	157.4	115.7	(99.5-133.7)	Female	24	20.4	117.4	(75.2-174.7)

Cervix Uteri

Female	8	7.0	113.9	(49.0-224.3)
--------	---	-----	-------	--------------

Colon / Rectum

Male	62	63.8	97.2	(74.5-124.6)
Female	63	62.5	100.8	(77.4-128.9)

Esophagus

Male	10	10.9	91.9	(44.0-169.0)
Female	2	3.1	nc	(nc-nc)

Hodgkin Lymphoma

Male	6	3.5	173.5	(63.3-377.6)
Female	4	2.8	nc	(nc-nc)

Kidney & Renal Pelvis

Male	17	18.0	94.6	(55.1-151.5)
Female	8	11.5	69.4	(29.9-136.8)

Larynx

Male	2	7.1	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)

Leukemia

Male	15	13.5	111.4	(62.3-183.7)
Female	8	11.1	72.0	(31.0-141.8)

Liver and Intrahepatic Bile Ducts

Male	4	8.6	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)

Lung and Bronchus

Male	80	81.0	98.8	(78.3-123.0)
Female	78	77.0	101.3	(80.0-126.4)

Oral Cavity & Pharynx

Male	16	15.7	102.0	(58.3-165.7)
Female	6	7.8	77.0	(28.1-167.6)

Ovary

Female	15	17.0	88.2	(49.3-145.4)
--------	----	------	------	--------------

Pancreas

Male	15	12.0	124.5	(69.6-205.4)
Female	21	13.6	154.9	(95.8-236.8)

Prostate

Male	147	169.3	86.8	(73.3-102.0)
------	-----	-------	------	--------------

Stomach

Male	10	10.8	92.3	(44.2-169.8)
Female	6	6.7	90.0	(32.9-195.9)

Testis

Male	4	6.3	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	8	5.1	156.3	(67.3-308.0)
Female	23	16.4	140.4	(89.0-210.7)

Uteri Corpus and Uterus, NOS

Female	32	32.8	97.4	(66.6-137.5)
--------	----	------	------	--------------

All Sites / Types

Male	540	569.4	94.8	(87.0-103.2)
Female	586	541.2	108.3	(99.7-117.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

355

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	167	172.4	96.9	(82.7-112.7)	Male	56	95.2	58.8	(44.4-76.4)
Female	70	69.3	101.0	(78.7-127.6)	Female	50	84.6	59.1	(43.9-78.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	33.6	50.6	(29.5-81.0)	Male	19	25.8	73.7	(44.3-115.1)
Female	31	29.7	104.3	(70.9-148.1)	Female	16	21.9	73.1	(41.7-118.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	4	5.0	nc	(nc-nc)	Male	94	88.6	106.1	(85.7-129.8)
Female	561	646.0	86.8	(79.8-94.3)	Female	100	88.7	112.8	(91.8-137.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	37	29.4	125.8	(88.6-173.5)	Male	57	60.9	93.6	(70.9-121.3)
<u>Colon / Rectum</u>					Female	32	32.8	97.5	(66.7-137.6)
Male	247	254.8	96.9	(85.2-109.8)	<u>Ovary</u>				
Female	256	279.4	91.6	(80.7-103.6)	Female	69	71.5	96.5	(75.1-122.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	45	42.4	106.2	(77.5-142.2)	Male	60	47.9	125.4	(95.7-161.4)
Female	15	13.5	111.1	(62.1-183.2)	Female	56	59.5	94.1	(71.1-122.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	15.8	57.1	(26.1-108.4)	Male	449	633.8	70.8	(64.4-77.7)
Female	14	14.1	99.4	(54.3-166.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	38	44.1	86.3	(61.0-118.4)
Male	69	69.4	99.5	(77.4-125.9)	Female	31	30.7	101.0	(68.6-143.3)
Female	49	48.2	101.7	(75.2-134.4)	<u>Testis</u>				
<u>Larynx</u>					Male	26	28.0	93.0	(60.7-136.3)
Male	25	27.2	92.0	(59.5-135.9)	<u>Thyroid</u>				
Female	11	8.1	136.2	(67.9-243.7)	Male	17	20.2	84.3	(49.1-135.0)
<u>Leukemia</u>					Female	41	70.4	58.3	(41.8-79.0)
Male	58	56.0	103.6	(78.6-133.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	42	50.3	83.5	(60.2-112.9)	Female	132	132.1	99.9	(83.6-118.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	44	33.6	131.1	(95.3-176.0)	Male	2001	2231.8	89.7	(85.8-93.7)
Female	17	14.0	121.5	(70.7-194.5)	Female	2119	2294.7	92.3	(88.5-96.4)
<u>Lung and Bronchus</u>									
Male	348	313.9	110.9	(99.5-123.1)					
Female	295	317.3	93.0	(82.7-104.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

356

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)

Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	11	6.3	174.2	(86.9-311.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	20	20.9	95.7	(58.4-147.9)
Female	0	0.1	nc	(nc-nc)	Female	11	17.0	64.6	(32.2-115.5)
<u>Lung and Bronchus</u>									
Male	0	2.9	nc	(nc-nc)					
Female	2	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

357

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	10.0	59.8	(21.8-130.1)	Male	12	6.2	193.7	(100.0-338.4)
Female	9	4.0	223.2	(101.9-423.8)	Female	6	5.3	113.6	(41.5-247.2)

Brain and Other Nervous System

Male	4	2.2	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)

Breast

Male	0	0.3	nc	(nc-nc)
Female	31	42.0	73.9	(50.2-104.8)

Cervix Uteri

Female	2	2.0	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	22	15.4	143.1	(89.6-216.6)
Female	17	16.5	102.7	(59.8-164.5)

Esophagus

Male	4	2.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)

Hodgkin Lymphoma

Male	0	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)

Kidney & Renal Pelvis

Male	4	4.5	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)

Larynx

Male	2	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)

Leukemia

Male	4	3.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	2.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)

Lung and Bronchus

Male	13	18.5	70.3	(37.4-120.2)
Female	11	18.2	60.3	(30.1-107.9)

Multiple Myeloma

Male	2	1.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)

Non-Hodgkin Lymphoma

Male	8	5.6	143.9	(62.0-283.7)
Female	3	5.2	nc	(nc-nc)

Oral Cavity & Pharynx

Male	6	4.3	140.0	(51.1-304.7)
Female	1	2.0	nc	(nc-nc)

Ovary

Female	6	4.5	133.6	(48.8-290.8)
--------	---	-----	-------	--------------

Pancreas

Male	5	2.9	172.0	(55.4-401.5)
Female	2	3.5	nc	(nc-nc)

Prostate

Male	31	39.5	78.5	(53.3-111.4)
------	----	------	------	--------------

Stomach

Male	4	2.6	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)

Testis

Male	4	1.6	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	1.4	nc	(nc-nc)
Female	7	4.6	151.8	(60.8-312.9)

Uteri Corpus and Uterus, NOS

Female	7	8.3	84.5	(33.9-174.1)
--------	---	-----	------	--------------

All Sites / Types

Male	145	137.3	105.6	(89.1-124.2)
Female	122	140.8	86.6	(71.9-103.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>				<u>Melanoma of Skin</u>			

Male	78	52.9	147.6	(116.6-184.2)	Male	42	23.8	176.6	(127.3-238.7)
Female	24	19.4	123.7	(79.3-184.1)	Female	23	18.2	126.5	(80.2-189.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.2	111.6	(48.1-220.0)	Male	4	7.5	nc	(nc-nc)
Female	5	6.4	77.9	(25.1-181.7)	Female	5	6.1	81.7	(26.3-190.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	1.5	344.6	(111.0-804.1)	Male	20	23.2	86.3	(52.7-133.3)
Female	175	155.1	112.9	(96.8-130.9)	Female	24	23.0	104.2	(66.7-155.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.7	88.3	(28.5-206.1)	Male	10	15.1	66.3	(31.7-122.0)
<u>Colon / Rectum</u>					Female	9	8.2	109.2	(49.8-207.2)
Male	64	75.2	85.1	(65.6-108.7)	<u>Ovary</u>				
Female	78	77.5	100.6	(79.5-125.6)	Female	14	17.4	80.5	(43.9-135.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	12.1	116.1	(63.4-194.8)	Male	11	14.1	78.0	(38.9-139.5)
Female	5	3.8	132.0	(42.5-307.9)	Female	18	16.8	107.4	(63.6-169.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.3	nc	(nc-nc)	Male	250	181.9	137.4	(120.9-155.5)
Female	3	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	13.1	114.5	(64.1-188.9)
Male	19	18.3	103.8	(62.4-162.0)	Female	5	8.5	58.7	(18.9-137.0)
Female	10	12.4	80.4	(38.5-147.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.0	nc	(nc-nc)
Male	7	7.6	92.3	(37.0-190.2)	<u>Thyroid</u>				
Female	2	2.1	nc	(nc-nc)	Male	0	3.8	nc	(nc-nc)
<u>Leukemia</u>					Female	7	11.8	59.4	(23.8-122.3)
Male	16	14.4	111.1	(63.5-180.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	12.4	121.3	(67.9-200.1)	Female	31	32.7	94.9	(64.5-134.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	8.8	102.7	(46.9-195.0)	Male	729	625.6	116.5	(108.2-125.3)
Female	2	3.8	nc	(nc-nc)	Female	603	579.2	104.1	(96.0-112.8)
<u>Lung and Bronchus</u>									
Male	103	94.0	109.5	(89.4-132.8)					
Female	90	87.6	102.7	(82.6-126.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;